Thermo Fisher Scientific announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for this common inflammatory skin condition in adolescent patients. The registry recently enrolled its first European Union patient, expanding its geographic footprint beyond North America, where the first patient was enrolled in December 2023.
This initiative addresses a critical unmet need for real-world evidence and adolescent-specific developmental and safety data related to novel therapies for AD. The registry complements the existing adult CorEvitas AD Registry, which was launched in 2020, further solidifying Thermo Fisher's presence in dermatology research.
The adolescent AD registry is the 11th independent registry from CorEvitas, part of Thermo Fisher Scientific’s PPD clinical research business. It will collect detailed prospective data to enable comparative safety and effectiveness research, including in-depth evaluation of comorbid medical conditions, growth, and maturation milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.